| abstract |
The present invention relates to pharmaceutical formulations comprising a fibroblast growth factor 21 polypeptide, for example, a modified FGF-21 polypeptide, such as PEG-FGF-21, and one or more stabilizers such as the chelator DPTA (acid diethylenetriaminepentaacetic). The formulations can be further stabilized by including a surfactant such as polysorbate 80 and / or adjusting the pH to about 7.1. Also provided are manufacturing methods, treatment methods, and kits comprising the formulation. This formulation is useful in the treatment of diseases and conditions associated with fibrosis. |